Dazodalibep

DB19025InvestigationalProtein Based Therapies

Dazodalibep is under investigation in clinical trial NCT06104124 (A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity).

Mechanism: Pharmacologically active on CD40 ligand
Curator reviewed
Also known as: PROTEIN VIB4920 (RECOMBINANT HUMAN TENASCIN C CD40 LIGAND-BINDING THIRD FIBRONECTIN TYPE III DOMAIN) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 19-AMINO ACID LINKER) FUSION PROTEIN WITH TENASCIN C CD40 LIGAND-BINDING THIRD FIBRONECTIN TYPE III DOMAIN (HUMAN
Code names: AMG-611 · MEDI-4920 · VIB-4920

Resolves to

Compound

UNIIHN5US76BWFCAS2245953-10-8

Targets

P29965CD40LG

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dazodalibep, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account